{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"39.500","floor":"34.500"},"ipodate":{"start":"2019-11-14 00:00:00","end":"2019-11-20 00:00:00"},"minimumcapital":"3989.81","subscribed":"114.23","marketcap":"306.88億","H_marketcap":"46.03億","pe":"80.48","codesrate":"100.00","link":"https://staticpdf.iqdii.com/stockdata/notice/03759/2019/2019111400072_c.pdf","ipopricing":"39.500","resultdate":"2019-11-27 00:00:00","enddate":"2019-11-20 00:00:00","listeddate":"2019-11-28 00:00:00","issuenumber":"11653.61萬","issuenumberhK":"5826.81萬","issuenumberother":"5826.80萬","grayprice":"42.85","sponsors":"高盛(亞洲)有限責任公司,中信里昂證券資本市場有限公司,東方融資(香港)有限公司","raisemoney":"434410.00萬","use":"1、約1,303.3百萬港元（或所得款項凈額約30%）將用于擴展中國實驗室及生產設施的產能及能力；\n2、約434.4百萬港元（或所得款項凈額約10%）撥付美國及英國業務的進一步擴張；\n3、約868.8百萬港元（或所得款項凈額約20%）將用于建立有關研發生物制劑的醫藥研發服務平臺；\n4、約651.6百萬港元（或所得款項凈額約15%）將用于擴展臨床開發服務實力及能力；\n5、約651.6百萬港元（或所得款項凈額約15%）將用于透過潛在收購在美國、歐洲、日本或中國提供醫藥研發服務且擁有尖端研發技術的合同研發服務及合同生產服務公司及/或其業務，來擴展我們的產能及/或能力；\n6、約434.4百萬港元（或所得款項凈額約10%）將用于一般企業用途及用作營運資金。","shares":100,"leadagent":"高盛(亞洲)有限責任公司,中信里昂證券有限公司,東方證券(香港)有限公司","bookrunners":"高盛(亞洲)有限責任公司,中信里昂證券有限公司,東方證券(香港)有限公司,華興證券(香港)有限公司","coordinator":"高盛(亞洲)有限責任公司,中信里昂證券有限公司,東方證券(香港)有限公司","firstDayOpen":"43.45","IsEiio":0,"Interestdays":7,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"高盛(亞洲)有限責任公司","code":"E03759","name":"康龍化成","fullname":"康龍化成(北京)新藥技術股份有限公司"},"institutioninfo":{"principaloffice":"中國北京北京經濟技術開發區泰河路6號1幢8層","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"樓柏良","secretary":"麥寶文","telephone":"(8610) 5733 0087","substantialshareholders":"中信并購基金(23.89%),君聯資本(17.92%),康龍控股有限公司(12.56%)","principalactivities":"公司是一家領先的全流程一體化醫藥研發服務平臺。","website":"http://www.pharmaron.com"},"managerinfo":[{"managername":"樓柏良","post":"董事長、首席執行官兼執行董事","rankno":1},{"managername":"樓小強","post":"首席運營官、總裁兼執行董事","rankno":2},{"managername":"鄭北","post":"執行副總裁兼執行董事","rankno":3}],"investorinfo":[{"institutionname":"Lake Bleu Prime Healthcare Master Fund Limited","shareholding":"7,931,600.0","percentage":6.81,"ReleaseDate":"2020-05-28 00:00:00","relatedparty":"清池資本(香港)有限公司","subsidiary":["Lake Bleu Prime Healthcare Master Fund Limited"],"InverstorType":"基金"},{"institutionname":"中國國有企業結構調整基金股份有限公司","shareholding":"7,931,600.0","percentage":6.81,"ReleaseDate":"2020-05-28 00:00:00","relatedparty":"國務院國資委","subsidiary":["中國誠通控股集團有限公司","中國國有企業結構調整基金股份有限公司","中國機械工業集團有限公司","中國商用飛機有限責任公司","中國西電集團公司"],"InverstorType":"公司"},{"institutionname":"OrbiMed Funds","shareholding":"5,948,700.0","percentage":5.1,"ReleaseDate":"2020-05-28 00:00:00","relatedparty":"OrbiMed Capital LLC","subsidiary":["OrbiMed Funds","Worldwide Healthcare Trust PLC"],"InverstorType":"基金"},{"institutionname":"Athos Asia Event Driven Master Fund","shareholding":"4,957,200.0","percentage":4.25,"ReleaseDate":"2020-05-28 00:00:00","relatedparty":"Athos Capital Limited","subsidiary":["Athos Asia Event Driven Master Fund"],"InverstorType":"基金"}],"TotalShareholdingPercentage":27.22},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":10}